Luminex (NSDQ:LMNX) said today that it closed its buy of Nanosphere (NSDQ:NSPH) through the purchase of 45.3 million shares at $1.70 per share, offering up $76.9 million for the company. The company said that in addition to the purchased shares, it sent notices of guaranteed deliver with respect to 953,173 shares, and that the merger was completed […]
Luminex Corp.
Luminex raises Nanosphere offer to $102m
Luminex (NSDQ:LMNX) said today that a 3rd-party offer for Nanosphere (NSDQ:NSPH) prompted it to raise its own $83 million bid for the company and its Verigene molecular diagnostics technology. Last week Luminex offered $1.35 pe share for Nanosphere and said it would also pay off some $25 million of Nanosphere’s debt. Today the company said a $1.50-per-share bid from an […]
Luminex pays $83m for Nanosphere
Luminex (NSDQ:LMNX) agreed to pay a total of $83 million to acquire Nanosphere (NSDQ:NSPH) and its Verigene molecular diagnostics technology. The $1.35-per-share, all-cash deal consists of a 15-day tender offer for NSPH shares by Luminex, followed by a merger to buy up and untendered shares, the companies said. It’s expected to close during the 2nd quarter, they […]
Mid-stream medtech company aims to cut costs, boost sales | MassDevice.com On Call
MASSDEVICE ON CALL — Implantable devices command huge revenues and often are the top-performing segments of some of the industry’s titans, but selling, general & administrative expenses often eat away at the bottom line.
FDA clears Ethicon’s 1st surgical set docs can assemble inside the body | Regulatory Roundup
Johnson & Johnson (NYSE:JNJ) Ethicon Endo-Surgery won FDA clearance for the 1st surgical instruments that can be assembled and disassembled inside the body during surgery.
Embryonic stem cells debut in eye treatment in Advanced Cell Tech’s first human trials | Regulatory Roundup
Advanced Cell Technology Inc. (OTC:ACTC) successfully dosed the first patients in clinical trials of stem cell implantation for blinding eye diseases, making it only the second company in the U.S. to win FDA permission to study a therapy derived from embryonic stem cells.
ACTC’s two trials involve implantation of retinal pigment epithelial cells derived from embryonic stem cells into patients with Stargardt’s macular dystrophy and dry age-related macular degeneration.
Cynosure picks up aesthetic laser business for $24.5 million | Acquisitions roundup
Cynosure Inc. (NSDQ:CYNO) announced the $24.5 million acquisition of the assets of Japan-based HOYA ConBio’s aesthetic laser business today.
The Westford, Mass.-based cosmetic laser device maker adds HOYA’s proprietary PhotoAcoustic energy technology to its product portfolio, which also includes the SmoothShapes cellulite reduction system.
The PhotoAcoustic technology uses high-speed energy waves to penetrate skin in nanoseconds, minimizing the amount of heat in each procedure.
AstraZeneca sells its med tech arm to Dentsply for $1.8 billion in cash | Deals Roundup
FDA review sends BioMimetic shares plunging despite solid Q1 growth | Earnings roundup
Shares of BioMimetic Therapeutics Inc. (NSDQ:BMTI) continued their slide today after plummeting 35.3 percent yesterday to close at $8.66 on news of the FDA’s dim view of its Augment bone graft product.
BD inks licensing deal with University College London | Distribution roundup
Here’s a roundup of companies announcing new distribution deals.
Steris profits dive as product shipments slow | Earnings roundup
MassDevice keeps a close eye on public medical device companies, tracking their quarterly sales and earnings reports. For the most recent filings, check out our Earnings Roundup, where we collect each quarter’s reports.
Here’s a quick rundown of a few releases over the past couple days:
